Low-molecular-weight heparin in the treatment of pulmonary embolism

Seminars in Vascular Surgery

Volumn 13, Issue 3, 2000, Pages 189-193

  Ageno, W ^a   Turpie, A G G ^a  

^a Hamilton Health Science Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; REVIPARIN; TINZAPARIN;

BLEEDING; CLINICAL TRIAL; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; FIBRINOLYTIC THERAPY; HOME CARE; HUMAN; LUNG EMBOLISM; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

ANTICOAGULANTS; CLINICAL TRIALS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, SUBCUTANEOUS; PULMONARY EMBOLISM; SAFETY; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 0033822750     PISSN: 08957967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Diagnostic utility of ultrasonography of leg veins in patients suspected of having pulmonary embolism
2. Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis
3. Initial treatment of venous thromboembolism
4. Antithrombotic therapy for venous thromboembolic disease
5. Pulmonary embolism
6. Acute pulmonary embolism: Clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER)
7. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy: The emerging theme of delayed recurrence
8. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis
9. A standard heparin nomogram for the management of heparin therapy
10. Optimal therapeutic level of heparin therapy in patients with venous thrombosis
11. Heparin and low molecular weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
12. Heparin induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin
13. Low-molecular-weght heparins: Pharmacological profile and product differentiation
14. Low molecular weight heparin
15. Comparison of efficacy and safety of low molecular weight heparin and unfractionated heparin in initial treatment of deep venous thrombosis: Meta-analysis
16. Treatment of deep venous thrombosis with low molecular weight heparins
17. Low molecular weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
18. Treatment of venous thrombosis with intravenous unfractionated heparin administered in hospital as compared with subcutaneous low molecular weight heparin administered at home
19. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
20. Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism: A dose ranging study
21. Subcutaneous low-molecular-weight-heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: An open randomized pilot study
22. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism
23. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism
24. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism
25. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis
26. Expanding eligibility for outpatients treatment of deep venous thrombosis and pulmonary embolism with low molecular weight heparin: A comparison of patient self-injection with homecare injection